These laboratory observations were then followed by several early phase clinical trials that showed significant efficacy of INO in acute lymphoblastic leukemia (ALL), ultimately prompting to its evaluation in a large, randomized trial in adults with relapsed/refractory CD22-positive B-cell ALL. Here, CD22 is linked to acute lymphoblastic leukemia.